Use of autoantibodies in breast cancer screening and diagnosis

Storr, Sarah J; Chakrabarti, Jayeta; Barnes, Anthony; Murray, Andrea; Chapman, Caroline J; Robertson, John FR

Abstract

Breast cancer is the most common cancer among women and accounts for 6% of all cancer deaths. Current screening modalities for breast cancer diagnosis include mammography, digital mammography and magnetic resonance imaging; however, there is still an urgent need to develop an alternative modality of screening for earlier diagnosis. Autoantibodies to tumor-associated autoantigens can be elicited in breast cancer patients. Tumor-associated antigens vary between cancers and can be the result of a number of different events, including mutation, overexpression or altered expression patterns. The inherent amplification of signals provided by the host’s own immune system to low levels of tumor-associated antigens in early disease provides a potential route to the early diagnosis of cancer. In addition, autoantibody responses in breast cancer have been correlated with patient survival and their response to treatment.

Citation

Storr, S. J., Chakrabarti, J., Barnes, A., Murray, A., Chapman, C. J., & Robertson, J. F. (2006). Use of autoantibodies in breast cancer screening and diagnosis. Expert Review of Anticancer Therapy, 6(8), 1215-1223. https://doi.org/10.1586/14737140.6.8.1215

• Journal Article Type: Article
• Online Publication Date: Jan 10, 2014
• Publication Date: 2006-08
• Deposit Date: Oct 12, 2020
• Journal: Expert Review of Anticancer Therapy
• Print ISSN: 1473-7140
• Electronic ISSN: 1744-8328
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• Volume: 6
• Issue: 8
• Pages: 1215-1223
• DOI: https://doi.org/10.1586/14737140.6.8.1215
• Keywords: Pharmacology (medical); Oncology
• Public URL: https://nottingham-repository.worktribe.com/output/4958814
• Publisher URL: https://www.tandfonline.com/doi/full/10.1586/14737140.6.8.1215